IMMUNOCELLULAR THERAPEUTICS

ImmunoCellular Therapeuti is a clinical-stage biotechnology company. It is engaged in developing immune-based therapies for the treatment of cancers which can elicit an immune response against several antigens. The company has developed ICT-107, which is a dendritic cell (DC) immunotherapy for the treatment of newly diagnosed glioblastoma multiforme (GBM), which is a lethal type of brain cancer. It develops Immunotherapies for treating cancer in which a patient's own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies.